Pentixapharm sits at the intersection of a high-prevalence indication and one of the fastest- growing fields of medicine: radiopharma. Following the recent capital increase, the company is now well positioned to enter Phase 3 with its lead diagnostic agent PentixaFor from a position of financial strength, with several catalysts ahead.
LÄS MER
